Patients select any 2-day combination for convenient twice-weekly dosing
Remind patients to maintain a routine by changing the patch on the same 2 days each week
Simple for you to write
Please see full prescribing information for OXYTROL
[1] OXYTROL® Prescribing Information. February 2003.
[2] Dmochowski RR, Davila GW, Zinner NR, et al, for the Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580-586.
[3] Data on file, Watson Pharma, Inc.
[4] Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237-242.
[5] Appel RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696-702.
[6] Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW.Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001;18:1029-1034.
[7] OXYTROL® Patient Prescribing Information.
